Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solithera’s Prospects Look Grim Following Complete Response Letter

Executive Summary

Even if Cempra has the funds to conduct another trial, there is no guarantee for approval; if approved, solithromycin’s labeling would likely limit use of the community-acquired pneumonia antibiotic.

Advertisement

Related Content

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Advisory Committee Recommendations Could Limit Use Of Solithera

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel